Show simple item record

dc.contributor.authorFruh, M.
dc.contributor.authorPanje, C. M.
dc.contributor.authorReck, M.
dc.contributor.authorBlackhall, Fiona H
dc.contributor.authorCalifano, Raffaele
dc.contributor.authorCappuzzo, F.
dc.contributor.authorBesse, B.
dc.contributor.authorNovello, S.
dc.contributor.authorGarrido, P.
dc.contributor.authorFelip, E.
dc.contributor.authorO'Brien, M.
dc.contributor.authorPaz Ares, L.
dc.contributor.authorde Marinis, F.
dc.contributor.authorWesteel, V.
dc.contributor.authorDe Ruysscher, D.
dc.contributor.authorPutora, P. M.
dc.date.accessioned2020-06-16T11:03:16Z
dc.date.available2020-06-16T11:03:16Z
dc.date.issued2020en
dc.identifier.citationM. Fruh, C. M. Panje, M. Reck et al. Choice of second-line systemic therapy in stage IV small cell lung cancer (SCLC) - A decision-making analysis amongst European lung cancer experts. Lung Cancer. 2020;146:6-11.en
dc.identifier.pmid32485661en
dc.identifier.doi10.1016/j.lungcan.2020.03.024en
dc.identifier.urihttp://hdl.handle.net/10541/623036
dc.description.abstractOBJECTIVES: Stage IV small cell lung cancer (SCLC) is associated with short survival and progression after first-line systemic therapy frequently occurs within months. Although topotecan is approved for second-line treatment, its efficacy is limited, and treatment heterogeneity exists. MATERIAL AND METHODS: The decision-making patterns for second line treatment of 13 European medical oncologists with expertise in SCLC were analyzed. RESULTS: The two criteria most relevant to decision-making were the performance status and the interval of recurrence since first-line treatment. With an interval of less than 3 months since the end of first-line chemotherapy, 62 % of the experts recommended cyclophosphamide, doxorubicin and vincristine (CAV) for fit patients and 54 % recommended topotecan for unfit patients. For an interval of more than 6 months, a clear consensus for a re-challenge with a platinum doublet was achieved (92 %). However, there was no consensus on the second-line therapy with an interval of 3-6 months since the end of first-line therapy. CONCLUSION: Real world practice may differ from recommendations in general guidelines and cannot always be directly derived from trial results as other factor such as habits, patient's preference, convenience or costs have to be factored in.en
dc.language.isoenen
dc.relation.urlhttps://dx.doi.org/10.1016/j.lungcan.2020.03.024en
dc.titleChoice of second-line systemic therapy in stage IV small cell lung cancer (SCLC) - A decision-making analysis amongst European lung cancer expertsen
dc.typeArticleen
dc.contributor.departmentDepartment of Medical Oncology/Hematology, Cantonal Hospital of St. Gallen, St. Gallen, Switzerlanden
dc.identifier.journalLung Canceren
dc.description.noteen]


Files in this item

This item appears in the following Collection(s)

Show simple item record